FDA Approves First Targeted Therapy for Non-Cystic Fibrosis Bronchiectasis

Brensocatib offers targeted inflammation control and reduced exacerbations for a serious chronic lung disease affecting hundreds of thousands in the U.S.

Brensocatib (Brinsupri), a first-in-class DPP-1 inhibitor, is now the first FDA-approved treatment for non-cystic fibrosis bronchiectasis, cutting annual exacerbations by up to 21% and potentially setting a new standard of care.

Study Details

Non-cystic fibrosis bronchiectasis is a progressive lung disease affecting about 500,000 people in the U.S. It cau…